KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exact Sciences (EXAS) EBITDA Margin (2016 - 2025)

Exact Sciences (EXAS) has disclosed EBITDA Margin for 16 consecutive years, with 9.4% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 11343.0% to 9.4% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.35%, a 3166.0% increase, with the full-year FY2025 number at 6.35%, up 3166.0% from a year prior.
  • EBITDA Margin was 9.4% for Q4 2025 at Exact Sciences, down from 3.0% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1.09% in Q3 2023 to a low of 122.84% in Q4 2024.
  • A 5-year average of 26.05% and a median of 15.16% in 2024 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -11235bps in 2024, then soared 11343bps in 2025.
  • Exact Sciences' EBITDA Margin stood at 46.74% in 2021, then surged by 54bps to 21.5% in 2022, then surged by 51bps to 10.49% in 2023, then tumbled by -1071bps to 122.84% in 2024, then surged by 92bps to 9.4% in 2025.
  • Per Business Quant, the three most recent readings for EXAS's EBITDA Margin are 9.4% (Q4 2025), 3.0% (Q3 2025), and 0.26% (Q2 2025).